UK-based Ubiquigent, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, has named Hozefa Amijee as head of business development (BD). 7 November 2022
US clinical-stage biopharma firm Rivus Pharmaceuticals has presented positive top-line results from a Phase IIa trial evaluating the safety and efficacy of HU6, a first-in-class controlled metabolic accelerator (CMA), to address liver fat and total body fat in patients with non-alcoholic fatty liver disease (NAFLD). 7 November 2022
British immunotherapy specialist Scancell has in-licensed the SNAPvax technology from Vaccitech, enabling it to formulate and manufacture Modi-2. 7 November 2022
British pharma major AstraZeneca has appointed Stefan Woxström as senior VP of Europe and Canada, replacing Iskra Reic, who becomes executive VP of vaccines and immune therapies. 7 November 2022
Italian contract development and manufacturing organization (CDMO) ReiThera is set to open a new viral vector production area at its facility in Italy. 3 November 2022
Exelixis and Cybrexa Therapeutics have entered into an exclusive collaboration agreement, giving the former the right to buy a first-in-class peptide-drug conjugate (PDC). 2 November 2022
US pharma major Eli Lilly has submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lebrikizumab, an investigational interleukin (IL)-13 inhibitor for the treatment of moderate-to-severe atopic dermatitis (AD). 2 November 2022
A new pilot program has been announced by the US Food and Drug Administration, aimed at facilitating readiness for certain products with accelerated clinical development timelines. 1 November 2022
China has banned UK pharma major GSK's Avodart (dutasteride) being sold in the country, effective from October 31,2022 to April 29, 2024. 1 November 2022
Terumo Corp’s Terumo Pharmaceutical Solutions (TPS) unit intends to expand its contract development and manufacturing services for parenteral drugs to global customers. 1 November 2022
The European Medicines Agency is to proceed with its review of a submission for a novel drug, vamorolone, for the treatment of Duchenne muscular dystrophy (DMD). 31 October 2022
The US Food and Drug Administration (FDA) has deferred action on the Biologics License Application (BLA) for the investigation Pompe disease drug cipaglucosidase alfa, the biologic component of AT-GAA, US biotech Amicus Therapeutics announced on Friday. 31 October 2022
German drug major Bayer’s Kerendia (finerenone), a first-in-class, non-steroidal mineralocorticoid receptor antagonist (ns-MRA), was recommended as part of a comprehensive treatment strategy for patients with chronic kidney disease (CKD) associated with type 2 diabetes. 28 October 2022
British firm PhoreMost has entered into a multi-target collaboration with Arvinas, a Connecticut, USA-basesd specialist in targeted protein degradation. 28 October 2022
Swiss drugmaker Roche has revealed new long-term data for Ocrevus (ocrelizumab), related to disease progression and healthcare costs in people with early-stage relapsing-remitting multiple sclerosis (RRMS). 27 October 2022
Taiwan biotech OrientPharma (OEP) has signed an exclusive agreement with the Italian rare disease drug developer Chiesi to bring two drugs and one clinical stage candidate to Taiwan and Southeast Asian countries. 27 October 2022
UK immunotherapy company Scancell Holdings has announced that John Chiplin intends to resign his role as executive chairman and non-executive director of the company for personal reasons. 26 October 2022
Australian clinical-stage biotech Immutep today announced that the Independent Data Monitoring Committee (IDMC) for the randomized, controlled Phase IIb TACTI-003 trial has reviewed initial safety data and recommended continuing the trial with no modifications. 26 October 2022
Symeres, a Netherlands-based contract research organization (CRO) and contract development manufacturing organization, has acquired Exemplify BioPharma, a USA-based CRO. 25 October 2022
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Abivax ABVX) today announced the results of an interim efficacy and safety analysis of an open-label maintenance (OLM) study that enrolled patients with ulcerative colitis (UC). 3 October 2024